Literature DB >> 16712930

Hypermethylation of CpG island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system (CNS) infiltration correlates with poorer prognosis.

Valéria A Paixão1, Daniel O Vidal, Otavia L Caballero, André L Vettore, Luiz G Tone, Karina Braga Ribeiro, Luiz Fernando Lopes.   

Abstract

Promoter hypermethylation occurs early in leukemogenesis and seems to be associated with poor prognosis in acute lymphoblastic leukemia (ALL). The methylation status of the promoter region of six genes was analyzed in 71 children with ALL using methylation specific PCR (MSP). Calcitonin (CALCA) and E-cadherin (CDH1) were the most frequently methylated genes in this group of patients. Considering the patients with central nervous system (CNS) infiltration, the estimated 2-year overall survival (OS) was 20% for those with methylation in CALCA promoter and 85% for those without (p=0.001). Our results suggest that the hypermethylation of CALCA promoter is a promising prognostic marker and may predict a higher risk for ALL patients with CNS infiltration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712930     DOI: 10.1016/j.leukres.2005.11.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC).

Authors:  Meiju Ji; Yong Zhang; Bingyin Shi; Peng Hou
Journal:  Diagn Pathol       Date:  2011-06-04       Impact factor: 2.644

2.  Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment.

Authors:  Huan Wang; Jianfang Rong; Qiaoyun Zhao; Conghua Song; Rulin Zhao; Sihai Chen; Yong Xie
Journal:  Dis Markers       Date:  2022-04-05       Impact factor: 3.434

3.  MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients.

Authors:  Camila Maria da Silva Martinelli; André van Helvoort Lengert; Flavio Mavignier Cárcano; Eduardo Caetano Albino Silva; Mariana Brait; Luiz Fernando Lopes; Daniel Onofre Vidal
Journal:  Oncotarget       Date:  2016-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.